Cartesian Therapeutics (RNAC) news
Recent news
Cartesian Therapeutics reports licensed pact with Westgene Biopharma
AInvest Wire · Jun 9, 2026Cartesian Therapeutics - Westgene to receive upfront and potential milestone payments under agreement
AInvest Wire · Jun 9, 2026Cartesian Therapeutics announces strategic licensing agreement with Westgene Biopharma to accelerate the development of in vivo CAR-T platform in autoimmune diseases
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) has announced a strategic licensing agreement with Westgene Biopharma to advance its in vivo CAR-T platform for the treatment of autoimmune diseases. The collaboration aims to enhance the development and delivery of Cartesian’s next-generation cell…
AInvest Wire · Jun 9, 2026Cartesian Therapeutics positive topline results 2B trial.
Cartesian Therapeutics positive topline results 2B trial. The biotech industry is witnessing remarkable progress, and Cartesian Therapeutics, a clinical-stage company specializing in mRNA cell therapy for autoimmune diseases, is leading the charge. Recently, the company reported promising updates…
AInvest Wire · Jul 2, 2024Oppenheimer starts Cartesian at outperform, cites lead drug potential
Oppenheimer starts Cartesian at outperform, cites lead drug potential The biopharmaceutical industry is continually seeking innovative solutions to address unmet medical needs. One such company at the forefront of this endeavor is Cartesian Therapeutics (RNAC), a clinical-stage biotech firm…
AInvest Wire · Jun 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.